Clinical Trials on Philadelphia Chromosome, Ph^1^, Absent

Total 161 results

Bristol-Myers Squibb

Completed

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia | Philadelphia-Positive Myeloid Leukemia

Belgium, Spain, United States, Italy, Argentina, Brazil, Canada, Germany, Peru, Puerto Rico, Singapore, South Africa, Taiwan, United Kingdom, Australia, France, Philippines, Sweden, Thailand, Russian Federation, China, Poland, Finland, Isra... and more
Novartis Pharmaceuticals

Recruiting

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Singapore, France, Germany, United Arab Emirates, Greece, Italy, Czechia, Hungary, United States, India, Oman, Malaysia, Korea, Republic of, Turkey, Bulgaria, Canada, Slovakia, United Kingdom, Argentina, Jordan, Romania, South Africa and more
Crystal Mackall, MD
California Institute for Regenerative Medicine (CIRM)

Active, not recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Minimal Residual Disease | CD19 Positive

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative

United States
Nanfang Hospital of Southern Medical University
Guangxi Medical University; Peking University People's Hospital; Sun Yat-Sen... and other collaborators

Unknown

TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Stem Cell Transplantation | Minimal Residual Disease | Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

China
Memorial Sloan Kettering Cancer Center
Jazz Pharmaceuticals

Withdrawn

Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older

Acute Lymphoblastic Leukemia (ALL) | Newly Diagnosed Philadelphia Chromosome Negative | Aged 60 Years or Older

United States
Goethe University

Completed

Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)

Philadelphia Positive Acute Lymphoblastic Leukemia

Germany
M.D. Anderson Cancer Center
Ascentage Pharma Group Inc.

Not yet recruiting

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Advanced Chronic Myeloid Leukemia | Philadelphia Chromosome-Positive Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Acute Lymphoblastic Leukemia in Remission

United States
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States
UNC Lineberger Comprehensive Cancer Center

Completed

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML - Philadelphia Chromosome | CML (Chronic Myelogenous Leukemia

United States
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Unknown

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Allogeneic Hematopoietic Stem Cell Transplantation | Minimal Residual Disease | Philadelphia Chromosome Positive Acute Lymphocytic Leukemia | Tyrosine Kinase Inhibitor

China
National Cancer Institute (NCI)

Completed

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

B-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditions

United States
Il-Yang Pharm. Co., Ltd.

Recruiting

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Chronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML, Refractory | CML - Philadelphia Chromosome

Turkey, Korea, Republic of, Russian Federation, Ukraine
Nanfang Hospital, Southern Medical University

Recruiting

A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL (ABC)

Acute Lymphoblastic Leukemia | Philadelphia Chromosome | Adult ALL | Philadelphia-Positive ALL | IKZF1 Gene Mutation

China
Novartis Pharmaceuticals

Recruiting

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Myeloid Leukemia, Philadelphia Positive

Korea, Republic of, Germany, France, United States, Greece, Hungary, Italy, Japan, Poland, Russian Federation, Thailand, Turkey, China, Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Minimal Residual Disease | Adult Acute Lymphoblastic Leukemia in Complete Remission

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

Iclusig PMS in CML or Ph+ALL Patients

Chronic Myeloid Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI); ADC Therapeutics S.A.

Recruiting

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 Positive

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Astex Pharmaceuticals, Inc.

Recruiting

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive | BCR-ABL1 Positive Chronic Myelogenous Leukemia | BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Completed

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Acute Leukemias of Ambiguous Lineage | Untreated Adult Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia

United States
Bristol-Myers Squibb

Completed

Rollover Study of BMS-354825 in Patients With CML and Ph+ALL

Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Minimal Residual Disease | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
Novartis Pharmaceuticals

Completed

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Chronic Myelogenous Leukemia | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

Japan
Novartis Pharmaceuticals

Terminated

Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib (MACS1532)

Philadelphia Positive (Ph+) Chronic Myeloid Leukemia

Russian Federation
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
Novartis Pharmaceuticals

Completed

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Germany, Australia, Netherlands, Spain, Korea, Republic of, France, Japan, Italy, Singapore, United States
Il-Yang Pharm. Co., Ltd.

Completed

Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Philadelphia Chromosome

India, Korea, Republic of, Thailand
Il-Yang Pharm. Co., Ltd.

Completed

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Bone Marrow Diseases | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Philadelphia Chromosome

Korea, Republic of, Indonesia, Thailand, Philippines
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Chronic Myeloid Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-positive

Netherlands, United States, Italy, Argentina, Austria, Brazil, Canada, Germany, Peru, United Kingdom, France, Korea, Republic of, Sweden, Finland, Australia, Israel, Belgium, Denmark, Norway, Switzerland
Crystal Mackall, MD

Recruiting

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Refractory Acute Lymphoblastic Leukemia | Minimal Residual Disease | CD19 Positive

United States
Rennes University Hospital
Novartis; Ministry of Health, France

Completed

Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children (ESPHALL)

Acute Lymphoblastic Leukemia | Philadelphia Chromosome

France
Novartis Pharmaceuticals

Completed

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. (DIALOG)

Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia

United States, France, Korea, Republic of, Thailand, Italy, Netherlands, Turkey, Hungary, Russian Federation, Spain, United Kingdom, Japan, Malaysia
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals; Incyte Corporation

Active, not recruiting

Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

Acute Lymphoblastic Leukemia

United States
Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML

Chronic Myeloid Leukemia

France, United States, Spain, Belgium, Singapore, Poland, Canada, Japan, United Kingdom, Taiwan, Hungary, Germany, Argentina, Russian Federation, Turkey, Colombia, Italy, South Africa, Brazil, Chile, China, Hong Kong, India, Korea, Republic... and more
University of Utah
Janssen, LP

Withdrawn

Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone

Acute Lymphoblastic Leukemia

United States
Pfizer

Completed

Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

Chronic Myeloid Leukemia

United States, Spain, Australia, Canada, Hong Kong, Singapore, United Kingdom, Germany, Netherlands, Chile, India, South Africa, Sweden, Peru, Argentina, Italy, Austria, Colombia, Brazil, China, Finland, Hungary, Korea, Republic of, M... and more
Novartis Pharmaceuticals

Completed

Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) (NICOLI)

Chronic Myeloid Leukemia

Germany
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Myelogenous Leukemia, Chronic

China
National Cancer Institute (NCI)

Active, not recruiting

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | T Acute Lymphoblastic Leukemia

United States
Exelixis

Terminated

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

Chronic Myeloid Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Italy
Asan Medical Center

Completed

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Leukemia

Korea, Republic of
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

Leukemia | Acute Lymphoblastic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia and other conditions

United States
Novartis Pharmaceuticals

Completed

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd)

Myelogenous Leukemia, Chronic

South Africa, Italy, Belgium, Japan, Taiwan, Turkey, Canada, Germany, Spain, Egypt, United States, Singapore, Austria, France, Netherlands, Sweden, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Russian Federation, Brazil, Hungar... and more
Bristol-Myers Squibb

Completed

A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (DASISION)

Myeloid Leukemia, Chronic

Germany, India, Japan, Korea, Republic of, Turkey, Chile, China, Spain, Australia, France, Poland, Mexico, Colombia, Belgium, Austria, Italy, Peru, Greece, Brazil, Czech Republic, Hungary, Russian Federation, Netherlands, Argentina, Den... and more
Pfizer

Completed

Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias

Chronic Myelogenous Leukemia

Japan

Clinical Trials on Philadelphia Chromosome, Ph^1^, Absent

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations